Buy Rating Affirmed for COMPASS Pathways Amid Promising Psilocybin Treatment Prospects and Strategic Market Positioning
RBC Capital Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $23
RBC Capital Remains a Buy on COMPASS Pathways (CMPS)
HC Wainwright & Co. Reiterates Buy on Compass Pathways, Maintains $120 Price Target
Buy Rating Affirmed for COMPASS Pathways Amid Progress in Pivotal Trials and Strong Financial Position
CCORF Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $48
Buy Rating Affirmed: COMPASS Pathways' Promising Clinical Trials Advance Psychedelic Therapeutics
TD Cowen Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $23
TD Cowen Remains a Buy on COMPASS Pathways (CMPS)
Maxim Group Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $22
Oppenheimer Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $25
Morgan Stanley Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $23
A Quick Look at Today's Ratings for COMPASS Pathways(CMPS.US), With a Forecast Between $23 to $48
Oppenheimer Sticks to Their Buy Rating for COMPASS Pathways (CMPS)
Compass Pathways Analyst Ratings
Canaccord Genuity Maintains Buy on Compass Pathways, Lowers Price Target to $48
Buy Rating Affirmed for COMPASS Pathways Amid Positive Clinical Trial Progress and Solid Financial Footing
Compass Pathways Price Target Maintained With a $120.00/Share by HC Wainwright & Co.
Compass Pathways Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Compass Pathways, Maintains $120 Price Target